Completed PHASE2 INTERVENTIONAL 2-arm NCT01068353

Safety and Tolerability of Etanercept in Alzheimer's Disease (STEADI-09)

A Phase 2, Double-blind, Placebo-controlled Study of the Safety and Tolerability of Etanercept in Patients With Alzheimer's Disease

Sponsor: Hampshire Hospitals NHS Foundation Trust

Conditions Alzheimer's Disease

Interventions Etanercept Placebo

Updated 5 times since 2017 Last updated: Apr 22, 2014 Started: Jan 31, 2011 Primary completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01068353, this PHASE2 trial focuses on Alzheimer's Disease and remains completed. Sponsored by Hampshire Hospitals NHS Foundation Trust, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hampshire Hospitals NHS Foundation Trust
University of Southampton
Wyeth is now a wholly owned subsidiary of Pfizer

Data source: University of Southampton

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Southampton, United Kingdom